Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 65 and 90 years old
- You have been diagnosed with Geographic Atrophy (a type of advanced dry age-related macular degeneration, which causes vision loss) in at least one eye
- The affected area in your eye is a specific size — not too small and not too large (confirm with trial site)
- The damaged area in your eye is positioned away from the edges of certain eye scan images (confirm with trial site)
- The damaged area has not spread into a specific region near the optic nerve at the back of your eye (confirm with trial site)
- You are already receiving a treatment called pegcetacoplan (also known as Syfovre) by injection into the eye, and have had at least one injection before joining the study
- Your vision, even with glasses or contact lenses, falls within a certain range — from roughly normal to moderately reduced (confirm with trial site)
- You are able to take part in a special vision sensitivity test and eye imaging required by the study
- You are willing and able to give your informed consent to take part
Who may not be able to join:
- You have had or currently have a "wet" form of macular degeneration (where abnormal blood vessels leak fluid) in the eye being studied
- You have a very strong glasses prescription or significant astigmatism (a common focusing problem with the eye)
- You have other eye conditions that could affect the study results, such as diabetic eye disease with swelling, a blocked vein in the eye, an inherited eye condition, or poorly controlled glaucoma
- You have cloudiness or blockages in your eye (such as a dense cataract, corneal scarring, or bleeding in the eye) that would prevent clear eye testing or imaging
- You have a serious health condition that the medical team believes could affect your ability to fully take part in, or complete, the trial (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Monika Fleckenstein, MD, University of Utah, Department of Ophthalmology
Phone: +1
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Slope of mesopic retinal sensitivity decline (dB/year) at predefined distances from the Geographic Atrophy (GA) border.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.